Key Facts Surrounding This News Item
- BTAI had returned 0.00% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.
More Info About BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation. View our full BTAI ticker page with ratings, news, and more.
Try StockNews.com Premium Today!
Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!